Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEO for Brain Radiation-Induced Metabolic Changes
NCT05720624Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Oct 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of oxaloacetate in malignant central nervous system neoplasm (4 cohorts), sponsored by Mayo Clinic. Primary endpoint: Feasibility of completing serial cerebrospinal fluid (CSF) collections for pharmacodynamic analyses at 3 months. Planned start Oct 2025; status: withdrawn.
02
Drugs
oxaloacetate
03
Conditions
malignant central nervous system neoplasm
Beyond the preview
Go deeper on NCT05720624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720624.